| Epidemiology of prostate cancer in Asian countries |
50 |
| Current treatment strategies for advanced prostate cancer |
18 |
| Clinical and molecular features of treatment-related neuroendocrine prostate cancer |
17 |
| Urinary biomarkers of prostate cancer |
17 |
| The Urological Association of Asia clinical guideline for urinary stone disease |
16 |
| Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine |
15 |
| Phenotyping of interstitial cystitis/bladder pain syndrome |
12 |
| Role of systemic inflammatory response markers in urological malignancy |
12 |
| Metabolic changes in patients with prostate cancer during androgen deprivation therapy |
11 |
| Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study |
11 |
| Prediction models for progression of non-muscle-invasive bladder cancer: A review |
11 |
| Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan |
10 |
| Pathophysiology of interstitial cystitis |
10 |
| Diagnosis and treatment of patients with prostatic abscess in the post-antibiotic era |
10 |
| Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review |
10 |
| Lessons learned from the management of adults who have undergone augmentation for spina bifida and bladder exstrophy: Incidence and management of the non-lethal complications of bladder augmentation |
9 |
| Predictive biomarkers for drug response in bladder cancer |
9 |
| Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome |
9 |
| Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients |
8 |
| Laparoscopic adrenalectomy using the lateral retroperitoneal approach: Is it a safe and feasible treatment option for pheochromocytomas larger than 6 cm? |
8 |
| Efficacy of novel beta(3)-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study |
8 |
| Treatment of male stress urinary incontinence using autologous adipose-derived regenerative cells: Long-term efficacy and safety |
8 |
| Benefits and limitations of animal models in partial bladder outlet obstruction for translational research |
8 |
| Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches |
7 |
| Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening |
7 |
| Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase randomized, double-blind, parallel, placebo- and tamsulosin-controlled study |
7 |
| Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan |
7 |
| Long-term safety and efficacy of the novel beta(3)-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study |
7 |
| Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer |
7 |
| Accuracy of elastic fusion biopsy in daily practice: Results of a multicenter study of 2115 patients |
7 |
| Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer |
7 |
| C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma |
7 |
| Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study |
7 |
| Local treatment for metastatic prostate cancer: A systematic review |
7 |
| Molecular pathogenesis of renal cell carcinoma: Impact of the anti-tumor miR-29 family on gene regulation |
6 |
| Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment? |
6 |
| Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stageT1 high-grade urothelial bladder cancer |
6 |
| Renal tumors in end-stage renal disease: A comprehensive review |
6 |
| Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p |
6 |
| Current status of prognostic factors in patients with metastatic renal cell carcinoma |
6 |
| Robot-assisted single-port radical prostatectomy: A phase 1 clinical study |
6 |
| Non-invasive assessment of kidney allograft fibrosis with shear wave elastography: A radiological-pathological correlation analysis |
6 |
| High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer |
6 |
| Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas |
6 |
| Extracellular vesicles: Toward a clinical application in urological cancer treatment |
6 |
| Novel thulium fiber laser for endoscopic enucleation of the prostate: A prospective comparison with conventional transurethral resection of the prostate |
6 |
| Current status and future perspective of robot-assisted radical cystectomy for invasive bladder cancer |
6 |
| Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma |
6 |
| Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis |
6 |
| Updates in endourological management of urolithiasis |
6 |
